Impact of Lactoferrin Supplementation on Respiratory Tract Infections in Older Nursing Home Residents: A Protocol for a Randomized Control Trial
Carl BurtonVivek SighRabie ShahzadEsther H. LanLauren BrinkNeil FawkesCheryl HarrisSteven S. WuAshlee KirchoffElham GhadishahTatiana NemanimMai PhamJoseph YusinZhaoping Li
0
Citation
0
Reference
10
Related Paper
Abstract:
Abstract Objectives To evaluate the impact of a dietary supplement within an elderly population who reside in a Community Living Center (CLC; VA Nursing Home), on the number of respiratory tract infections (RTIs) during a 90-day study period. Methods This is a randomized, double-blind, placebo-controlled study to evaluate the impact of bovine Lactoferrin (bLf) on RTIs in an elderly nursing home population in the US. Subjects will be residents of the CLC and screened within 21 days prior to starting study supplementation. Eligible participants were at least 55 years of age, able to eat and drink and expected to reside at the CLC for the duration of the study. Consent was obtained from the study participant or their legally recognized representative decision maker. Participants will be excluded if: receiving tube feeds or specialized diets for eating disorders; immunocompromised; have a life expectancy of less than six months; or allergic to study products. Results Subjects will be randomized in a ratio of 1:1 to either investigational (600 mg of bLf) or (placebo arms. All participants will take study supplement by mouth daily for 90 days. Subjects will be assessed daily for RTI symptoms. Blood and saliva will be collected at 45 and 90 days. Ad hoc assessments and a nasal sample will take place if a subject develops a protocol-defined RTI. Conclusions The primary outcome will be number of RTIs over the 90-day study period. Secondary outcomes include severity and duration of RTI symptoms, symptoms associated with RTIs, number of RTI complications, and nasopharyngeal swab at onset of RTI, Other secondary outcomes include the following, all measured at baseline, day 45 and day 90: quality of life by questionnaire, weight, saliva markers, laboratory testing and immunological markers. An exploratory endpoint is vaccine specific inflammatory panel (influenza and Sars-Cov2) measured upon vaccination during supplement period. RTI number, severity, duration and complications and medically confirmed adverse events will be compared between the placebo and investigational groups. Funding Sources RB/Mead Johnson & Company.Keywords:
Lactoferrin
Respiratory tract
Abstract Objectives To evaluate the impact of a dietary supplement within an elderly population who reside in a Community Living Center (CLC; VA Nursing Home), on the number of respiratory tract infections (RTIs) during a 90-day study period. Methods This is a randomized, double-blind, placebo-controlled study to evaluate the impact of bovine Lactoferrin (bLf) on RTIs in an elderly nursing home population in the US. Subjects will be residents of the CLC and screened within 21 days prior to starting study supplementation. Eligible participants were at least 55 years of age, able to eat and drink and expected to reside at the CLC for the duration of the study. Consent was obtained from the study participant or their legally recognized representative decision maker. Participants will be excluded if: receiving tube feeds or specialized diets for eating disorders; immunocompromised; have a life expectancy of less than six months; or allergic to study products. Results Subjects will be randomized in a ratio of 1:1 to either investigational (600 mg of bLf) or (placebo arms. All participants will take study supplement by mouth daily for 90 days. Subjects will be assessed daily for RTI symptoms. Blood and saliva will be collected at 45 and 90 days. Ad hoc assessments and a nasal sample will take place if a subject develops a protocol-defined RTI. Conclusions The primary outcome will be number of RTIs over the 90-day study period. Secondary outcomes include severity and duration of RTI symptoms, symptoms associated with RTIs, number of RTI complications, and nasopharyngeal swab at onset of RTI, Other secondary outcomes include the following, all measured at baseline, day 45 and day 90: quality of life by questionnaire, weight, saliva markers, laboratory testing and immunological markers. An exploratory endpoint is vaccine specific inflammatory panel (influenza and Sars-Cov2) measured upon vaccination during supplement period. RTI number, severity, duration and complications and medically confirmed adverse events will be compared between the placebo and investigational groups. Funding Sources RB/Mead Johnson & Company.
Lactoferrin
Respiratory tract
Cite
Citations (0)
Lactoferrin
Respiratory tract
Cite
Citations (0)
Respiratory tract
Cite
Citations (0)
Trivalent influenza vaccine
Antibody titer
Respiratory tract
Cite
Citations (26)
Cefamandole
Cite
Citations (5)
Respiratory tract
Cite
Citations (1)
Bronchial secretions obtained during bronchoscopic examination of 60 children suffering from respiratory tract infections were studied for the concentration of immunoglobulins, anti-proteolytic factors, lactoferrin, and lysozyme. Eleven children having bronchial asthma without a history of chronic or recurrent infections of the respiratory tract were designated as a control. The results were analysed in relation to clinical diagnosis (chronic bronchitis, bronchitis, bronchiectasis) or to the local status of bronchial mucosa at the time of bronchoscopy (no inflammation, inflammation, inflammation with documented bacterial infection). The statistical analysis of the results revealed a decrease of lactoferrin and locally produced IgA in the group of children suffering from bronchitis and chronic bronchitis. Samples infected with Haemophilus species had significantly higher concentration of lactoferrin than any other group. Similarly, albumin in this group was higher than in the other group except that other bacteria were present. Samples infected with Haemophilus also had increased concentrations of S-IgA, IgG, and anti-proteolytic factors when compared with the group without local inflammation.
Lactoferrin
Respiratory tract
Chronic bronchitis
Immunoglobulin A
Cite
Citations (1)
Respiratory tract
Cite
Citations (0)
Respiratory tract
Skin test
Cite
Citations (0)
Recurrent respiratory tract infections in children are common. It means that children are repeatedly exposed to external pathogens within a certain time, and the clinical symptoms are reciprocating. This article carries out nursing intervention on children’s respiratory tract infection through comprehensive nursing methods and analyzes the intervention effect. Moreover, this paper uses a controlled trial to study the nursing methods of recurrent respiratory tract infections in children. In addition, this paper determines and screens test samples according to relevant standards, conducts different nursing methods on samples of different groups, and compares them with the same indicators. Finally, this paper combines mathematical statistics to make statistics of experimental results and draws tables and statistical graphs. By comparing multiple parameters, it can be seen that the comprehensive nursing intervention has a good effect on the nursing of children with respiratory tract infection compared with the traditional nursing intervention, so this nursing method can be expanded in the future.
Respiratory tract
Cite
Citations (2)